Targeting MEK in non-small cell lung cancer.

Abstract excerpt

The mitogen-activated protein kinase (MAPK or MEK) pathway modulates tumor cell survival and proliferation in non-small cell lung cancer (NSCLC). Unlike RAS or EGFR, activating mutations in MEK are exceedingly rare in NSCLC. Instead, enhanced activation of the MEK pathway is often linked to increased signaling by upstream oncogenic driver mutations. Thus far, MEK inhibitor monotherapy has shown little promise....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Protein Kinase Inhibitors
• Share to Molecular Targeted Therapy